ADXN - Addex Therapeutics Ltd

ADXN - Addex Therapeutics Ltd

https://www.addextherapeutics.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders

GlobeNewswire • 2 months, 2 weeks ago • score: 0.14

Ad Hoc Announcement Pursuant to Art. 53 LR ...

Addex Shareholders Approve All Resolutions at Annual General Meeting

GlobeNewswire • 2 months, 3 weeks ago • score: 0.12

Ad Hoc Announcement Pursuant to Art. 53 LR ...

Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025

GlobeNewswire • 2 months, 4 weeks ago • score: 0.09

Geneva, Switzerland, June 18, 2025 - Addex Therapeutics ( SIX/NASDAQ: ADXN ) , a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will issue its Q1 2025 Financial Results ...

Addex to Present Positive GABAB PAM Chronic Cough Data at the 10th American Cough Conference

GlobeNewswire • 3 months, 1 week ago • score: 0.10

Geneva, Switzerland, June 5, 2025 - Addex Therapeutics ( SIX/NASDAQ: ADXN ) , a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that preclinical data from its gamma-aminobutyric ...

Addex Convenes Annual General Meeting 2025

GlobeNewswire • 3 months, 1 week ago • score: 0.10

Geneva, Switzerland, June 3, 2025 - Addex Therapeutics ( SIX: ADXN and Nasdaq: ADXN ) , a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its 2025 Annual General Meeting will ...

Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies

GlobeNewswire • 4 months ago • score: 0.13

Ad Hoc Announcement Pursuant to Art. 53 LR ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Addex Therapeutics Ltd, a developing-stage biopharmaceutical company, discovers, develops and markets small molecule pharmaceuticals for central nervous system (CNS) disorders in Switzerland. The company is headquartered in Geneva, Switzerland.

52W High

$11.84

52W Low

$6.51

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.77

Valuation

As of 2025-03-31 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-0.76

EV/Revenue (<3 favorable)

27.10

P/S (TTM) (<3 favorable)

37.77

P/B (<3 favorable)

0.79

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

0.00%

Institutions (25–75% balanced)

0.04%

Shares Outstanding

1,069,100

Float

26,107,100

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-03-31 (Overview)

Revenue (TTM)

246,190

Gross Profit (TTM)

-519,059

EPS (TTM)

-7.57

Profit Margin (>10% good)

35.22%

Operating Margin (TTM) (higher better)

-8.53%

ROE (TTM) (>15% strong)

-1.63%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.70

Momentum

Bearish momentum

Value

0.2425

Previous

-0.0422

Trend

Rising

Signal Cross

Crossed Up Today

As of

Sep. 12, 2025